Eagle Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $85.9M | Buy |
309,589
+63,385
| +26% | +$17.6M | 0.44% | 84 |
|
|
2024
Q2 | $59.9M | Sell |
246,204
-12,044
| -5% | -$2.93M | 0.32% | 111 |
|
|
2024
Q1 | $39.6M | Sell |
258,248
-4,617
| -2% | -$708K | 0.2% | 142 |
|
|
2023
Q4 | $50.3M | Buy |
262,865
+185
| +0.1% | +$35.4K | 0.27% | 125 |
|
|
2023
Q3 | $46.5M | Buy |
262,680
+3,725
| +1% | +$660K | 0.28% | 125 |
|
|
2023
Q2 | $49.2M | Sell |
258,955
-4,493
| -2% | -$853K | 0.27% | 123 |
|
|
2023
Q1 | $52.8M | Sell |
263,448
-225
| -0.1% | -$45.1K | 0.31% | 111 |
|
|
2022
Q4 | $61.6M | Buy |
263,673
+153
| +0.1% | +$35.7K | 0.38% | 102 |
|
|
2022
Q3 | $52.7M | Buy |
263,520
+2,217
| +0.8% | +$444K | 0.34% | 104 |
|
|
2022
Q2 | $38.1M | Buy |
261,303
+5,366
| +2% | +$783K | 0.24% | 138 |
|
|
2022
Q1 | $41.8M | Buy |
255,937
+607
| +0.2% | +$99.1K | 0.21% | 144 |
|
|
2021
Q4 | $43.7M | Buy |
255,330
+1,549
| +0.6% | +$265K | 0.19% | 156 |
|
|
2021
Q3 | $47.9M | Sell |
253,781
-2,128
| -0.8% | -$402K | 0.22% | 158 |
|
|
2021
Q2 | $43.4M | Sell |
255,909
-249
| -0.1% | -$42.2K | 0.19% | 166 |
|
|
2021
Q1 | $36.3M | Buy |
256,158
+14,078
| +6% | +$2M | 0.16% | 190 |
|
|
2020
Q4 | $31.5M | Sell |
242,080
-19,794
| -8% | -$2.57M | 0.18% | 182 |
|
|
2020
Q3 | $38M | Buy |
261,874
+54
| +0% | +$7.83K | 0.2% | 175 |
|
|
2020
Q2 | $38.7M | Buy |
+261,820
| New | +$38.7M | 0.22% | 157 |
|
|
2013
Q4 | – | Sell |
-96,415
| Closed | -$6.18M | – | 616 |
|
|
2013
Q3 | $6.18M | Buy |
+96,415
| New | +$6.18M | 0.03% | 448 |
|